Michele Stone has completed her PhD in Biochemistry and Molecular Biology from University of Maryland, Baltimore and Postdoctoral studies also at the University of Maryland in the fields of Physiology and Neuorscience. She is currently the Executive Director of Vaccines at Liquidia Technologies, a premier biotechnology company focused on development of particulate based drug products to provide global health solutions. She has published more than 15 patents and many articles in reputed journals. She has a PMP certification and brings a perspective of life cycle management to product development. Michele Stone has completed her PhD in Biochemistry and Molecular Biology from University of Maryland, Baltimore and Postdoctoral studies also at the University of Maryland in the fields of Physiology and Neuorscience. She is currently the Executive Director of Vaccines at Liquidia Technologies, a premier biotechnology company focused on development of particulate based drug products to provide global health solutions. She has published more than 15 patents and many articles in reputed journals. She has a PMP certification and brings a perspective of life cycle management to product development.

Vaccines & Vaccination